Acne vulgaris - Pipeline Insight, 2024

Acne vulgaris - Pipeline Insight, 2024

DelveInsight’s, “Acne vulgaris - Pipeline Insight, 2024,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acne vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acne vulgaris Understanding

Acne vulgaris: Overview

Acne vulgaris is an inflammatory disorder of the pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by Cutibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA). It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. Acne may appear in adolescence, and it persists through the early thirties. Acne is more common in males than in females. Urban populations are more affected than rural populations. About 20% of the affected individuals develop severe acne, which results in scarring. Some races appear to be more affected than others. Acne occurs by hypersensitivity of the sebaceous glands to a normal circulating level of androgens, which are aggravated by P. acnes and inflammation. Acne vulgaris is diagnosed clinically. However, in women of childbearing age, one should ask for a history of hirsutism or dysmenorrhea. If positive, then levels of testosterone, LH, FSH, and DHEA should be ordered. Topical retinoids like retinoic acid, adapalene, and tretinoin are used alone or with other topical antibiotics or benzoyl peroxide. Retinoic acid is the best comedolytic agent, available as 0.025%, 0.05%, 0.1% cream, and gel. Azelaic acid is antimicrobial and comedolytic available 15% or 20% gel. It can also be used in postinflammatory pigmentation of acne. An oral contraceptive containing low dose estrogen 20 mcg along with cyproterone acetate as anti-androgens are used for severe recurrent acne.

Acne vulgaris Emerging Drugs Chapters

This segment of the Acne vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acne vulgaris Emerging Drugs

• IDP126: Bausch Health Americas, Inc.

A fixed dose combination of adapalene, benzoyl peroxide and clindamycin phosphate gel formulation, designated as IDP 126, is being developed by Bausch. In June 2021, Ortho Dermatologics, a Bausch Health Company, announced results from its second phase III trial investigating the safety and efficacy of IDP-126 (Ortho Dermatologics)) for the treatment of acne vulgaris in patients 9 years and older. This study, a phase III, multicenter, randomized, double-blind, vehicle-controlled trial, met all coprimary endpoints by week 12. The endpoints were the absolute change from baseline in inflammatory lesion count and noninflammatory lesion count, and percentage of patients who achieved treatment success. The treatment success was defined as clear or almost clear skin in the Evaluator’s Global Severity Score (EGSS).

• DMT310: Dermata Therapeutics

DMT310 is a lead product candidate, developed from our Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications. It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties.Currently it is being evaluated in Phase II stage of development to treat acne vulgaris.

Further product details are provided in the report……..

Acne vulgaris: Therapeutic Assessment

This segment of the report provides insights about the different Acne vulgaris drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Acne vulgaris

There are approx. 22+ key companies which are developing the therapies for Acne vulgaris. The companies which have their Acne vulgaris drug candidates in the mid to advanced stage, i.e. Phase III include, Bausch Health Americas, Inc.

Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

• Late-stage products (Phase III )
• Mid-Stage products (Phase II)
• Early-stage products ( Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

Acne vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Oral

● Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Peptide
• Antibiotics

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acne vulgaris: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acne vulgaris therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acne vulgaris drugs.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Acne vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve Acne vulgaris.

Acne vulgaris Report Insights

• Acne vulgaris Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acne vulgaris Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acne vulgaris drugs?
• How many Acne vulgaris drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acne vulgaris?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acne vulgaris therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acne vulgaris and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novan, Inc.
• Bausch Health Americas, Inc.
• AOBiome LLC
• Ascletis Pharmaceuticals
• AnaptysBio, Inc.
• Botanix Pharmaceuticals
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
• Xenon Pharmaceuticals Inc.
• Origimm Biotechnology
• Boston Pharmaceuticals
• Kintor Pharma
• Dermavant Sciences
• Eligo Bioscience
• Cassiopea, Inc.
• BioPharmX
• Madam Therapeutics
• SiSaf

Key Products

• SB204
• IDP-126
• B244
• ASC40
• Imsidolimab
• BTX 1503
• UHE-101
• XPF-005
• ORG101
• BOS-356
• BPX-01
• Aminolevulinic acid (ALA)